May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Heidelberg Retinal Tomograph Imaging Over Time: How Frequently Should Patients Be Tested to Reliably Detect Disease Progression?
Author Affiliations & Notes
  • V.M. F. Owen
    School of Science, Nottingham Trent University, Nottingham, United Kingdom
  • D.P. Crabb
    School of Science, Nottingham Trent University, Nottingham, United Kingdom
  • N.G. Strouthidis
    Moorfields Eye Hospital, Glaucoma Research Unit, London, United Kingdom
  • D.F. Garway–Heath
    Moorfields Eye Hospital, Glaucoma Research Unit, London, United Kingdom
  • Footnotes
    Commercial Relationships  V.M.F. Owen, None; D.P. Crabb, None; N.G. Strouthidis, Heidelberg Engineering F; D.F. Garway–Heath, Carl Zeiss Meditec C; Heidelberg Engeneering F; Laser Diagnostic Technologies F, R; Talia Technologies F.
  • Footnotes
    Support  VMFO supported by educational grant from Pfizer (Pharmacia) Ltd
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2531. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V.M. F. Owen, D.P. Crabb, N.G. Strouthidis, D.F. Garway–Heath; Heidelberg Retinal Tomograph Imaging Over Time: How Frequently Should Patients Be Tested to Reliably Detect Disease Progression? . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2531.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To characterise the noise in Heidelberg Retinal Tomograph (HRT) measurement of neuroretinal rim area (RA) in order to make recommendations on the optimal frequency of imaging in follow–up for detecting disease progression in glaucoma. Methods: Patients with primary open angle glaucoma or ocular hypertension (OH) were recruited to two studies: one of test–retest HRT imaging (74 patients) and the other of longitudinal imaging over 6 years (238 patients). Global RA measurement variability was characterised by fitting theoretical distributions to the observed data. The rate of loss in RA was estimated from the longitudinal data using linear regression. Computer simulations of disease progression were performed by specifying noise–free progression rates estimated from the clinical data, and then adding noise from the distribution derived from the clinical data. Rates of sensitivity and specificity in detecting disease progression (defined as a negative regression slope with P<0.05) were investigated for stable eyes and progressing eyes. Fixed follow–up periods and different rates of imaging were investigated. Results: Measurement variability was not Normally distributed and was best characterised by the Hyperbolic distribution, giving good fit to averages whilst allowing for extreme values. Rates of loss of RA were small (mean loss per year in OH patients who converted to glaucoma according to visual fields = 0.015 mm2, standard deviation = 0.018 mm2). Poor rates of detection (sensitivity = 24%, specificity = 95%) were observed by imaging 2 times per year over a follow–up period of 3 years. Detection rates improved by imaging more frequently (for example, 4 times a year for 5 years gave sensitivity = 76%, specificity = 95%). Conclusions: The noise in HRT measurement is well characterised by the Hyperbolic distribution, allowing for experiments on the frequency of testing to detect various rates of disease progression. Sensitivity of detection improves with more frequent testing. However, in the clinical situation follow–up is not fixed but instead continues sequentially until progression is detected, resulting in deteriorating specificity with repeated testing, thus corrective statistical methods are required to maintain specificity. This work is based on average rates of loss, however it is possible to develop similar methods which will allow detection to be tailored for individual patients.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×